The collaborative
AI platform for
pathologists
We help pathologists accelerate the diagnostic process with reliability and excellence
Challenges in pathology
Shortage of Pathologists
About a billion slides generated annually around the globe. In 2017 less than 1% of them was scanned. In 2021 the percentage was around 10%. This will delay even more the diagnostic process for patients that will not even be diagnosed. Moreover, by 2030 the number of active pathologists will drop by 30% aprox. compared to 2010 numbers, resulting in a gap between supply and demand of 6.000 pathologists.
Still using 150-year-old methods
Current diagnostic approaches in pathology are manual, slow and inefficient, taking up to 40 minutes per slide. The foundations of pathology analysis have not changed for over 150 years. Digital technologies must help the field to improve and to become more efficient and more scalable.
KOMOMBO provides the solution
State of the art technology,
from future to the present
We have built a platform based on federated learning that will democratize pathology analysis.
The platform is sustained on the following technologies:
PROCESS
AUTOMATION
DEEP
LEARNING
DATA
ANNOTATION
BLOCKCHAIN
COLLABORATION
TELEPATHOLOGY
FEDERATED
LEARNING
REPORTING
& ANALYTICS
VISUALIZATIONS
& ANALYSIS
KOMOMBO assists in spotting shapes, patterns and the relative location of objects on image through computer vision.
This annotated input is read by the specialist, reducing the time spent on the monotonous and repetitive task of counting cells and searching for traces of illness. Instead, they can analyze the traces spotted by KOMOMBO that will be ready to confirm.
Federated Learning,
the key to confidentiality
and collaboration
KOMOMBO gives the most from AI without moving patient images from hospitals servers, gets the outcome from the algorithm across multiple decentralized servers holding local data samples, without exchanging them.
Data is kept in the original server
Our experts leverage data science techniques to treat distributed data within the hospital’s local server, avoiding centralizing data and compromising GDPR compliance. This ensures that the institution keeps the complete ownership of data.
Our goal is not to only allow the usage of the platform but to use their data together and jointly enrich the pathology portfolio getting to help more patients everyday around the world.
Federated Learning,
the key to confidentiality
and collaboration
KOMOMBO gives the most from AI without moving patient images from hospitals servers, gets the outcome from the algorithm across multiple decentralized servers holding local data samples, without exchanging them.
Data is kept in the original server
Our experts leverage data science techniques to treat distributed data within the hospital’s local server, avoiding centralizing data and compromising GDPR compliance. This ensures that the institution keeps the complete ownership of data.
Our goal is not to only allow the usage of the platform but to use their data together and jointly enrich the pathology portfolio getting to help more patients everyday around the world.
What’s New
Check the latest media appearances and stay up to date with Komombo’s progress:
Komombo, Hospital Clinic of Barcelona and Roche Diagnostics
Colorectal cancer is one of the cancers with the highest incidence in the world, along with lung, prostate and breast cancer…
Komombo speeds up lPF diagnosis
Hospital Clínic of Barcelona (HCB), recognized as the best hospital in Spain and ranked 21st in the world, and the «Fundació Clínic per a la…»
E-nnova Health 2022 Award
Enzyme has received the E-nnova Health 2022 award for the initiative «Development of Artificial Intelligence algorithms»
The Team
Who is behind the project?
A high performance team with proven experience and expertiese in Machine Learning and Federated Learning projects, blockchain and computer vision solutions that has been awarded by IBM for successful projects with AI solutions.
Jorge Juan Fernández
Managing Director
Jorge has more than 20 years of experience. He has been Director of E-Health within the Innovation Department at Hospital Sant Joan de Déu Barcelona, Director of Moebio and Director of Innovation of EIT Health. Today he is Venture Partener at Nina Capital and regularly acts as advisor and mentor to healthcare and life sciences startups and entrepreneurial acceleration programs across Europe.
Anna Rosés Martí
COO
Coming from FMCG and Pharma companies, Anna has worked at different departments in multinational business moving from Product Manager and Key Account Manager to Pharma eCommerce Manager. Currently, she focuses her efforts on business strategy and digitalization. She holds an International Master in Management from EADA and a Master of Internet Businesses from ISDI.
José Antonio Torre
CTO
José Antonio is CTO and Head of Architecture at Enzyme. Technical visionary with a deep knowledge of technology and its aplication, he has lead innovation and digital transformation projects. In the past few years he has entered the AI applied to health in order to improve people’s quality of life.
ADVISORY BOARD
Business
Joseph Sullivan
CEO at Emmetropes, Executive Committee Member at AECOS (American-European Congress of Ophthalmic Surgery)
Pau Ivars
External Consultant International Marketing in Diagnostic
Juan Carlos Serra
CEO at Marketinred, Healthcare Masters Director at EADA and College of Pharmacists of Barcelona, Founder at Fertypharm
Clinical
Fèlix Lluis
MD, PhD, Surgeon and Emeritus Researcher at the Institute of Sanitary and Biomedical Research of Alicante (ISABAL)
Technical
Jesús Cerquides
PhD, Scientific Researcher, CSIC IIIA
Juan A. Rodriguez
Scientific Researcher, CSIC IIIA
José Parra
PhD, Assistant Professor in Blokchain and Digitalization in the Copenhagen Business School
Luis Artiles
Chief Innovation at Enzyme, PhD
Yan Bello
Advisor
Work with us
Do you want to join our team?
We are looking for people with startup spirit and entrepreneur mindset that will help us walk the extra mile, are you one of them? Reach us:
jobs@komombo.ai
Strategic alliances
We are increasing our capabilities and growing beyond by working together with first-class partners and collaborators.
